- Home
- MSB vs OLMA Comparison
MSB vs OLMA Comparison
Compare MSB & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- OLMA
- Stock Information
- Founded
- MSB 1961
- OLMA 2006
- Country
- MSB United States
- OLMA United States
- Employees
- MSB N/A
- OLMA N/A
- Industry
- MSB Metal Mining
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- MSB Basic Materials
- OLMA Health Care
- Exchange
- MSB Nasdaq
- OLMA Nasdaq
- Market Cap
- MSB 379.4M
- OLMA 420.2M
- IPO Year
- MSB N/A
- OLMA 2020
- Fundamental
- Price
- MSB $33.25
- OLMA $6.28
- Analyst Decision
- MSB
- OLMA Strong Buy
- Analyst Count
- MSB 0
- OLMA 5
- Target Price
- MSB N/A
- OLMA $26.25
- AVG Volume (30 Days)
- MSB 65.5K
- OLMA 1.2M
- Earning Date
- MSB 01-01-0001
- OLMA 03-10-2025
- Dividend Yield
- MSB 4.98%
- OLMA N/A
- EPS Growth
- MSB 714.88
- OLMA N/A
- EPS
- MSB 7.00
- OLMA N/A
- Revenue
- MSB $26,785,162.00
- OLMA N/A
- Revenue This Year
- MSB N/A
- OLMA N/A
- Revenue Next Year
- MSB N/A
- OLMA N/A
- P/E Ratio
- MSB $4.48
- OLMA N/A
- Revenue Growth
- MSB 85.21
- OLMA N/A
- 52 Week Low
- MSB $15.93
- OLMA $4.60
- 52 Week High
- MSB $32.04
- OLMA $16.78
- Technical
- Relative Strength Index (RSI)
- MSB 79.02
- OLMA 49.67
- Support Level
- MSB $26.19
- OLMA $5.46
- Resistance Level
- MSB $28.69
- OLMA $5.93
- Average True Range (ATR)
- MSB 1.48
- OLMA 0.50
- MACD
- MSB 0.53
- OLMA 0.24
- Stochastic Oscillator
- MSB 99.86
- OLMA 99.38
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of the assets held. The company's principally wholly-owned segment is the iron ore mining segment and it generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.